FDFT1 | OmnibusX

I. Expression across cell types

Name	Number of supported studies	Average coverage
B cell	21 studies	27% ± 11%	Explore
memory B cell	17 studies	25% ± 10%	Explore
natural killer cell	16 studies	26% ± 8%	Explore
CD4-positive, alpha-beta T cell	16 studies	31% ± 19%	Explore
epithelial cell	16 studies	31% ± 16%	Explore
naive B cell	16 studies	24% ± 7%	Explore
CD8-positive, alpha-beta T cell	15 studies	31% ± 18%	Explore
regulatory T cell	15 studies	32% ± 16%	Explore
ciliated cell	13 studies	34% ± 13%	Explore
type II pneumocyte	12 studies	30% ± 14%	Explore
conventional dendritic cell	12 studies	26% ± 15%	Explore
astrocyte	12 studies	28% ± 9%	Explore
endothelial cell	12 studies	26% ± 9%	Explore
CD16-positive, CD56-dim natural killer cell, human	11 studies	25% ± 7%	Explore
basal cell	11 studies	32% ± 18%	Explore
oligodendrocyte	11 studies	33% ± 11%	Explore
gamma-delta T cell	11 studies	28% ± 12%	Explore
T cell	10 studies	23% ± 6%	Explore
naive thymus-derived CD4-positive, alpha-beta T cell	10 studies	21% ± 4%	Explore
club cell	9 studies	31% ± 11%	Explore
naive thymus-derived CD8-positive, alpha-beta T cell	9 studies	26% ± 12%	Explore
goblet cell	9 studies	32% ± 17%	Explore
mucosal invariant T cell	9 studies	21% ± 3%	Explore
CD16-negative, CD56-bright natural killer cell, human	9 studies	21% ± 4%	Explore
CD4-positive, alpha-beta memory T cell	8 studies	33% ± 18%	Explore
classical monocyte	8 studies	24% ± 8%	Explore
mature NK T cell	8 studies	22% ± 5%	Explore
fibroblast	8 studies	24% ± 6%	Explore
CD8-positive, alpha-beta memory T cell	7 studies	31% ± 17%	Explore
connective tissue cell	7 studies	22% ± 5%	Explore
smooth muscle cell	7 studies	27% ± 7%	Explore
oligodendrocyte precursor cell	7 studies	27% ± 14%	Explore
macrophage	7 studies	22% ± 6%	Explore
plasmacytoid dendritic cell	7 studies	28% ± 7%	Explore
type I pneumocyte	6 studies	22% ± 11%	Explore
secretory cell	6 studies	38% ± 19%	Explore
effector memory CD8-positive, alpha-beta T cell	6 studies	22% ± 3%	Explore
neuron	6 studies	32% ± 10%	Explore
dendritic cell	6 studies	34% ± 17%	Explore
mucus secreting cell	6 studies	34% ± 12%	Explore
abnormal cell	6 studies	27% ± 8%	Explore
hematopoietic precursor cell	5 studies	35% ± 12%	Explore
ionocyte	5 studies	35% ± 10%	Explore
respiratory goblet cell	5 studies	34% ± 11%	Explore
non-classical monocyte	5 studies	24% ± 7%	Explore
myofibroblast cell	5 studies	19% ± 3%	Explore
transit amplifying cell	5 studies	22% ± 5%	Explore
retinal ganglion cell	5 studies	62% ± 30%	Explore
hematopoietic stem cell	5 studies	32% ± 13%	Explore
brush cell	5 studies	35% ± 13%	Explore
pericyte	5 studies	23% ± 6%	Explore
retinal pigment epithelial cell	5 studies	44% ± 16%	Explore
mast cell	5 studies	25% ± 10%	Explore
duct epithelial cell	4 studies	36% ± 19%	Explore
exhausted T cell	4 studies	34% ± 17%	Explore
microglial cell	4 studies	20% ± 3%	Explore
pro-B cell	4 studies	31% ± 8%	Explore
amacrine cell	4 studies	27% ± 11%	Explore
retinal cone cell	4 studies	21% ± 3%	Explore
alveolar macrophage	4 studies	19% ± 3%	Explore
effector CD4-positive, alpha-beta T cell	4 studies	50% ± 15%	Explore
effector CD8-positive, alpha-beta T cell	4 studies	48% ± 16%	Explore
effector memory CD4-positive, alpha-beta T cell	4 studies	40% ± 20%	Explore
monocyte	4 studies	24% ± 6%	Explore
GABAergic neuron	4 studies	32% ± 10%	Explore
glutamatergic neuron	4 studies	38% ± 17%	Explore
erythrocyte	4 studies	30% ± 21%	Explore
plasma cell	3 studies	41% ± 19%	Explore
squamous epithelial cell	3 studies	39% ± 23%	Explore
progenitor cell	3 studies	23% ± 4%	Explore
GABAergic amacrine cell	3 studies	36% ± 14%	Explore
placental villous trophoblast	3 studies	53% ± 15%	Explore
common myeloid progenitor	3 studies	34% ± 23%	Explore
lymphocyte	3 studies	23% ± 1%	Explore
myeloid cell	3 studies	22% ± 2%	Explore
immature B cell	3 studies	25% ± 2%	Explore
precursor B cell	3 studies	39% ± 6%	Explore
serous secreting cell	3 studies	27% ± 1%	Explore
Mueller cell	3 studies	19% ± 4%	Explore
chondrocyte	3 studies	19% ± 3%	Explore
T follicular helper cell	3 studies	23% ± 2%	Explore
germinal center B cell	3 studies	26% ± 7%	Explore
luminal hormone-sensing cell of mammary gland	3 studies	22% ± 5%	Explore
leukocyte	3 studies	21% ± 2%	Explore
effector memory CD8-positive, alpha-beta T cell, terminally differentiated	3 studies	21% ± 6%	Explore
double negative thymocyte	3 studies	40% ± 18%	Explore
hepatocyte	3 studies	47% ± 33%	Explore

II. Expression across tissues

Name	Number of supported studies	Average coverage
lung	12 studies	27% ± 14%	Explore
brain	12 studies	24% ± 9%	Explore
peripheral blood	11 studies	25% ± 5%	Explore
eye	6 studies	21% ± 7%	Explore
lymph node	4 studies	19% ± 4%	Explore
intestine	4 studies	19% ± 4%	Explore
pancreas	3 studies	23% ± 10%	Explore
kidney	3 studies	18% ± 2%	Explore
bone marrow	3 studies	20% ± 4%	Explore
liver	3 studies	37% ± 14%	Explore

Tissue	GTEx Coverage	GTEx Average TPM	GTEx Number of samples	TCGA Coverage	TCGA Average TPM	TCGA Number of samples
stomach	100%	7401.95	359 / 359	100%	118.38	286 / 286
intestine	100%	7497.64	965 / 966	100%	135.61	527 / 527
prostate	100%	5959.75	245 / 245	100%	102.23	500 / 502
skin	100%	8640.94	1809 / 1809	100%	150.90	470 / 472
brain	99%	5606.17	2627 / 2642	100%	95.53	705 / 705
bladder	100%	6127.33	21 / 21	99%	127.00	501 / 504
esophagus	100%	7435.14	1442 / 1445	99%	113.38	182 / 183
breast	100%	6367.25	459 / 459	99%	93.52	1109 / 1118
lung	100%	7811.03	576 / 578	99%	95.36	1149 / 1155
ovary	100%	5537.42	180 / 180	99%	74.17	426 / 430
uterus	100%	6081.68	170 / 170	99%	97.83	453 / 459
thymus	100%	4264.13	651 / 653	98%	51.04	592 / 605
pancreas	95%	2855.19	312 / 328	99%	91.60	177 / 178
liver	99%	5404.67	224 / 226	95%	60.70	387 / 406
adrenal gland	100%	10386.66	258 / 258	94%	110.10	216 / 230
kidney	100%	4959.39	89 / 89	91%	37.84	822 / 901
adipose	100%	5620.94	1204 / 1204	0%	0	0 / 0
eye	0%	0	0 / 0	100%	152.71	80 / 80
lymph node	0%	0	0 / 0	100%	94.71	29 / 29
muscle	100%	7588.52	803 / 803	0%	0	0 / 0
spleen	100%	4278.33	241 / 241	0%	0	0 / 0
tonsil	0%	0	0 / 0	100%	123.95	45 / 45
ureter	0%	0	0 / 0	100%	38.61	1 / 1
blood vessel	100%	5109.17	1332 / 1335	0%	0	0 / 0
peripheral blood	99%	7730.73	922 / 929	0%	0	0 / 0
heart	92%	3576.20	794 / 861	0%	0	0 / 0
abdomen	0%	0	0 / 0	0%	0	0 / 0
bone marrow	0%	0	0 / 0	0%	0	0 / 0
diaphragm	0%	0	0 / 0	0%	0	0 / 0
gingiva	0%	0	0 / 0	0%	0	0 / 0
nasal cavity	0%	0	0 / 0	0%	0	0 / 0
nasopharynx	0%	0	0 / 0	0%	0	0 / 0
nose	0%	0	0 / 0	0%	0	0 / 0
placenta	0%	0	0 / 0	0%	0	0 / 0
spinal column	0%	0	0 / 0	0%	0	0 / 0

III. Associated gene sets

GO_0045338	Biological process	farnesyl diphosphate metabolic process
GO_0006695	Biological process	cholesterol biosynthetic process
GO_0006694	Biological process	steroid biosynthetic process
GO_0005783	Cellular component	endoplasmic reticulum
GO_0016020	Cellular component	membrane
GO_0005789	Cellular component	endoplasmic reticulum membrane
GO_0051996	Molecular function	squalene synthase activity
GO_0004310	Molecular function	farnesyl-diphosphate farnesyltransferase activity
GO_0005515	Molecular function	protein binding
GO_0004311	Molecular function	farnesyltranstransferase activity
GO_0046872	Molecular function	metal ion binding

IV. Literature review

[source]

Gene name	FDFT1
Protein name	Squalene synthase (SQS) (SS) (EC 2.5.1.21) Squalene synthase (SQS) (SS) (EC 2.5.1.21) (FPP:FPP farnesyltransferase) (Farnesyl-diphosphate farnesyltransferase) (Farnesyl-diphosphate farnesyltransferase 1) Farnesyl-diphosphate farnesyltransferase 1
Synonyms	hCG_17749
Description	FUNCTION: Catalyzes the condensation of 2 farnesyl pyrophosphate (FPP) moieties to form squalene. Proceeds in two distinct steps. In the first half-reaction, two molecules of FPP react to form the stable presqualene diphosphate intermediate (PSQPP), with concomitant release of a proton and a molecule of inorganic diphosphate. In the second half-reaction, PSQPP undergoes heterolysis, isomerization, and reduction with NADPH or NADH to form squalene. It is the first committed enzyme of the sterol biosynthesis pathway. . FUNCTION: Catalyzes the condensation of 2 farnesyl pyrophosphate (FPP) moieties to form squalene. . FUNCTION: Catalyzes the condensation of 2 farnesyl pyrophosphate (FPP) moieties to form squalene. . FUNCTION: Catalyzes the condensation of 2 farnesyl pyrophosphate (FPP) moieties to form squalene. . FUNCTION: Catalyzes the condensation of 2 farnesyl pyrophosphate (FPP) moieties to form squalene. .
Accessions	Q6IAX1 A0AA34QVU5 ENST00000220584.9 [P37268-1] ENST00000528812.5 [P37268-2] ENST00000622850.3 [P37268-2] A0A1W2PQ47 ENST00000615631.4 [P37268-1] ENST00000710774.1 [P37268-1] ENST00000525607.5 ENST00000525954.5 ENST00000530337.6 [P37268-1] P37268 ENST00000530337.5 ENST00000443614.6 [P37268-5] ENST00000532266.5 ENST00000528729.2 E9PNJ2 E9PS69 ENST00000647178.2 [P37268-1] ENST00000525283.5 ENST00000710780.1 [P37268-2] ENST00000710775.1 [P37268-1] E9PJG4 E9PSH1 ENST00000647069.3 [P37268-5] ENST00000528643.5 [P37268-3] ENST00000525900.5 ENST00000710781.1 [P37268-2] ENST00000710778.1 [P37268-3] E9PNM1 E9PQ90 ENST00000529464.5 ENST00000530664.5 [P37268-2] ENST00000710773.1 [P37268-2]

FDFT1 report

I. Expression across cell types

II. Expression across tissues

III. Associated gene sets

IV. Literature review